Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP
Tonix Pharmaceuticals — Q2 2026 Earnings Presentation
16 slides from Tonix Pharmaceuticals's earnings presentation, Aug 10, 2026
Slide 1: Second Quarter 2026 Financial Results and Operational Highlights
Second Quarter 2026 Financial Results and Operational Highlights AUGUST 10, 2026 NASDAQ: TNXP PO6158 August 10, 2026 1675 © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the Company’s expected financial performance, the Company’s anticipated cash runway, the Co
Slide 3: Tonix's Second Quarter 2026 Earnings Call
Tonix’s Second Quarter 2026 Earnings Call Demonstrating progress as Tonix focuses on commercial and development pipeline execution • ~$11 million in net sales in 2Q’26 (197% QoQ growth) TONMYA Launch • Growth across our key metrics Performance • ~43% coverage currently across all covered lives after
Slide 4: Strong TONMYA Performance in the Second Quarter
Strong TONMYA Performance in the Second Quarter Reflects strategic execution and value of TONMYA as the first approved treatment for fibromyalgia in 15+ years; first-line, non-opioid, designed for daily bedtime, long-term use 2Q Net Sales 2Q Key Metrics QoQ Growth Prescriptions ~$11M 12,592 100% New
Slide 5: Advancing Our Strategy
Advancing Our Strategy Second Quarter and Recent Highlights Market Access Sales Marketing Medical Affairs • 2 commercial coverage • Initially targeting 25K • Move Fibro Forward: • High-touch KOL agreements with GPOs HCPs who write ~70% of disease awareness engagements • Managed Medicare prescription
Slide 6: TNX-102 SL to Treat MDD: Targeting Disturbed Sleep
TNX-102 SL1 to Treat MDD: Targeting Disturbed Sleep Phase 2 potentially pivotal study The Opportunity Study Design Upcoming Milestone • Patients: Targeting ~360 enrolled patients 21M+ • Enrolling: Adults in the U.S. who are 18+ and currently experiencing a moderate to Adults in the U.S. severe major
Slide 7: TNX-4800: Differentiated Approach to Lyme Disease Prevention in the U.S.
TNX-48001: Differentiated Approach to Lyme Disease Prevention in the U.S Long-acting, human monoclonal antibody targeting OspA of Borrelia burgdorferi, engineered for an extended half-life The Opportunity Planned Study* Upcoming Milestones • Participants: ~3,300 87M • Targeting: Adults 18+ who live
Slide 8: Financial Highlights
Financial Highlights ZEMBRACE SYMTOUCH, TOTAL NET REVENUE TONMYA NET REVENUE TOSYMRA NET REVENUE $11.0M Second quarter 2026 + $2.5M Second quarter 2026 = $13.5M Second quarter 2026 CASH & EQUIVALENTS $176.2M As of June 30, 2026, with no debt Full income statement, balance sheet, and cash flow statem
Slide 9: Tonix is Strategically Executing for the Future
Tonix is Strategically Executing for the Future 2026 Priorities Execute on Advance mid- Drive sustainable TONMYA launch stage clinical growth to create programs value for all shareholders 9 © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 10: Thank you
Thank you 10 © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 11: TONMYA Important Safety Information (1 of 2)
TONMYA® (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (1 of 2) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TONMYA is contraindicated: In patients with hypersensitivity to cyclobenzaprine
Slide 12: TONMYA Important Safety Information (2 of 2)
TONMYA® (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (2 of 2) IMPORTANT SAFETY INFORMATION (CONT’D) ADVERSE REACTIONS The most common adverse reactions (incidence ≥2% and at a higher incid
Slide 13: ZEMBRACE Important Safety Information (1 of 2)
ZEMBRACE® Important Safety Information (1 of 2) ZEMBRACE SymTouch (ZEMBRACE) can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: • Discomfort in the center of your chest tha
Slide 14: ZEMBRACE Important Safety Information (2 of 2)
ZEMBRACE® Important Safety Information (2 of 2) ZEMBRACE may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cra
Slide 15: TOSYMRA Important Safety Information (1 of 2)
TOSYMRA® Important Safety Information (1 of 2) TOSYMRA® can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop TOSYMRA and get emergency medical help if you have any signs of heart attack: • Discomfort in the center of your chest that lasts for
Slide 16: TOSYMRA Important Safety Information (2 of 2)
TOSYMRA® Important Safety Information (2 of 2) TOSYMRA may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramp
Tonix Pharmaceuticals Holding — Q2 2026 Earnings Presentation on 6ix